For Immediate Release
March 5, 2014
Media Contact
Jim Palma
Jim@targetcancer.info
TargetCancer Grants $150,000 in Rare Can...
of 1

David Webster Press Release 12345

Published on: Mar 4, 2016
Published in: Healthcare      
Source: www.slideshare.net


Transcripts - David Webster Press Release 12345

  • 1. For Immediate Release March 5, 2014 Media Contact Jim Palma Jim@targetcancer.info TargetCancer Grants $150,000 in Rare Cancer Research Funding Rare cancer research foundation awards largest research initiative in organization history. Cambridge, MA (March 5,2014) – TargetCancer,a non-profit organization committed to innovative research of rare and lesser known cancers, announced $150,000 in new rare cancer research grant funding. TargetCancer awarded $100,000 to support cholangiocarcinoma research at the Massachusetts General Hospital Cancer Center,and $50,000 to support a new esophageal cancer collaboration at the Dana-Farber Cancer Institute. The $150,000 in new grant funding marks the largest round of research support in TargetCancer history. TargetCancer’s support of Dr. NabeelBardeesy’s Laboratory marks the fourth year of an ongoing commitment to build a comprehensive cholangiocarcinoma research program. The $100,000 grant to the Bardeesy Laboratory will support ongoing cholangiocarcinoma research and provide testing to better understand the genetic makeup of tumors, the nature of specific mutations, and the efficacy of new drug treatments. In addition, this grant supports the ongoing operations of the TargetCancer Cholangiocarcinoma Cell Line Bank at Massachusetts GeneralHospital, created by TargetCancer in 2012. In January 2014, TargetCancer created a new collaboration between Adam Bass,MD, and Michael Goldberg, Ph.D.,at the Dana-Farber Cancer Institute. The $50,000 grant funds a collaborative effort to identify new drug targets,as well potential combination genetic and immunotherapeutic drug therapies for esophageal cancer. Reflecting upon TargetCancer,Dr. Bass said, “I think that TargetCancer is making efforts that clearly are much larger than the financial investments they are making in individual labs. I think they are putting a lot of thought into how you can bring new teams of people who can build newer projects, newer approaches to build something bigger and to have a much longer lasting impact.” About Target Cancer TargetCancer promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer directly supports initiatives at the forefront of cancer treatment by funding innovative research,fostering collaborations, and raising awareness among scientists, clinicians, and patients. TargetCancer was founded by Paul Poth, a Boston-based attorney. In 2007, at age 38, Paul was diagnosed with cholangiocarcinoma, an extremely rare form of cancer. Rare cancersare poorly researched,if at all, because the funding simply isn’t there. It was this fact that drove Paul to create TargetCancer. After fighting for close to two years, Paul passed away in August 2009, but his fight, and his passion, lives on through TargetCancer. ###

Related Documents